Efficacy and safety of immune checkpoint inhibitors combined with anti-angiogenic therapy for frail patients with advanced biliary tract malignancies
Objective:To investigate the efficacy and safety of immune checkpoint inhibitors combined with anti-angiogenic drugs in the treatment of frail patients with advanced biliary tract malignancies.Methods:From January 2020 to December 2022,frail patients with advanced biliary malignancies di-agnosed at the Oncology Center in Renmin Hospital of Wuhan University were prospectively screened and included during the treatment with immune checkpoint inhibitors in combination with antiangiogen-ic drugs,and the efficacy and safety were summarized.Results:Among the 33 patients,13 cases of gallbladder carcinoma,17 cases of intrahepatic cholangiocarcinoma,and 3 cases of extrahepatic chol-angiocarcinoma.A total of 18 cases received first-line treatment and 15 cases received second-line treatment.The objective response rate(ORR)and disease control rate(DCR)were 66.7％and 90.9％,respectively.Median progression-free time(PFS)and median overall survival(OS)were 8.1 and 13.7 months,respectively.Grade 3 treatment-related adverse events(TRAEs)were observed in 7 patients(21.2％),while no grade 4 or 5 TRAEs were found.Conclusion:Immune checkpoint in-hibitors combined with anti-angiogenic drugs have significant clinical effects and good safety in the treatment of advanced biliary malignancies,providing a new option for advanced biliary malignancies.
NETL
NSTL
万方数据
